Shaily Engineering Plastics Limited — Investor Meet, 20-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Shaily Engineering Plastics has announced a board meeting to consider the financial results for the quarter and half-year.

Q4 FY25 revenue rose 28% YoY to INR217.8 Cr, with EBITDA up 51% to INR54.6 Cr and margin expanding 380 bps to 25.1%. PAT grew 48% to INR28.6 Cr (13.1% margin). For FY25, revenue reached INR787 Cr (+22%), EBITDA INR178 Cr (+45%) at 22.7% margin, and PAT INR93 Cr (+63%) at 11.8% margin. ROCE and ROE were 24.4% and 18.5%.

Healthcare grew 53% to INR165 Cr (21% of revenue), driven by IP-led GLP-1 pen injectors; capacity expansion with INR150 Cr capex aims to raise healthcare to 30% of revenues. Consumer and industrial segments grew 17% and 12% respectively.

Management emphasized next-gen pens with simplified designs and innovation in medical devices. Growth is backed by new client wins in regulated markets like Canada and Brazil. Capex plans target ~30 million pens in FY26 (70% IP-led). Margin expansion is expected on scale and mix, with cautious confidence on capacity ramp-up linked to confirmed customer demand.

Shaily continues scaling high-growth medical devices, diversifying revenue and strengthening export presence with solid execution.